evipedia.ai
← Back

Medium-Chain Triglycerides for Health & Longevity

Evidence Review created on 10/21/2026 using AI4L / Opus 5.5

Also known as: MCT, MCTs, MCT Oil, Medium-Chain Triacylglycerols, Caprylic/Capric Triglyceride, Tricaprylin, Tricaprilin, Tricaprin, Axona, AC-1202, AC-1204

Motivation

Medium-chain triglycerides are fats built from shorter fatty acids than those found in most foods. They occur naturally in coconut and palm kernel oils and are sold as a clear, flavorless oil or powder. Because the body absorbs and burns them quickly, part of each dose is turned by the liver into ketones, an alternative fuel the brain can use when its handling of sugar falters with age.

These oils were first produced in the 1950s for people who could not digest ordinary fats. They later drew interest for weight control and as a way to supply extra fuel to the ageing brain, and a purified form has been tested as a treatment for Alzheimer’s disease. Today they are a common ingredient in coffee blends, sports products and low-carbohydrate eating plans.

This review examines what human studies show about these fats for body weight and brain function in later life. It also covers side effects, practical use, and the quality and funding of the research behind each claim.

Benefits - Risks - Protocol - Conclusion

Expert commentary explaining how MCTs (medium-chain triglycerides, fats built from 6- to 12-carbon fatty acids) are metabolized and why they are studied for brain and weight health.

Of the priority experts, FoundMyFitness (Rhonda Patrick), Peter Attia, Chris Kresser, Life Extension and Lifespan.io have relevant content. Andrew Huberman mentions MCTs only in passing, as an option during “fat fasting” (consuming only fat until the eating window opens) in an episode on fasting, too briefly to qualify.

Grokipedia

Medium-chain triglyceride

Broad encyclopedic entry covering MCT chemistry, production, U.S. regulatory status, clinical nutrition uses and claimed effects on weight and ketosis (raised blood ketones); useful background, though health claims are weighed less critically.

Examine

Medium-Chain Triglycerides

Examine grades MCT effects on body fat, muscle function and cognition, lists studied doses (2–80 g/day), and flags that many weight and cognition trials were manufacturer-funded.

ConsumerLab

Coconut Oil and Medium Chain Triglycerides (MCT) Oil Review — Semi-Solid and Liquid Oils & Supplements

ConsumerLab tested coconut and MCT oils: all passed, but the cost of 8 g of MCTs varied over 20-fold. The public summary explains label checks for caprylic and capric acid content.

Systematic Reviews

Systematic reviews and meta-analyses of oral MCT for body weight, cognition, blood lipids and side effects.

Mechanism of Action

Unlike long-chain fats, MCTs are split quickly in the gut and pass straight to the liver through the portal vein (the vessel from gut to liver) without needing bile, packaging into chylomicrons (fat-transport particles) or the carrier enzyme CPT1 (carnitine palmitoyltransferase 1, which shuttles long fats into mitochondria). The liver burns them by beta-oxidation (the mitochondrial fat-burning pathway) and converts the surplus into ketones, mainly beta-hydroxybutyrate and acetoacetate.

  • Brain fuel: In mild cognitive impairment (memory or thinking decline short of dementia), 30 g/day raised brain ketone use 230% on scans, glucose uptake unchanged (Fortier et al., 2019).
  • Chain length matters: C8 (caprylic acid, 8 carbons) is about three times more ketogenic (ketone-producing) than C10 (capric acid, 10 carbons) and six times more than C12 (lauric acid, the main coconut-oil fat) (St-Pierre et al., 2019).
  • Direct fatty-acid actions: Decanoic acid (C10) blocks AMPA receptors (glutamate receptors that drive nerve excitation) and stimulates mitochondrial growth, a ketone-independent explanation for anti-seizure effects (Augustin et al., 2018).
  • Energy balance: Rapid oxidation slightly raises energy expenditure (St-Onge & Jones, 2002) and lowers food intake at later meals (Maher & Clegg, 2021).

Competing view: typical doses raise ketones only to about 0.3–0.5 mmol/L, and the NOURISH AD trial by product maker Cerecin blamed its failure partly on low ketone formation (Henderson et al., 2020), so the ketone pathway may be too weak to matter. MCTs are not metabolized by cytochrome P450 drug enzymes, and ketones return toward baseline within hours.

Historical Context & Evolution

MCTs were first produced in the 1950s in the United States from fatty acids left over from coconut-oil processing (Watanabe & Tsujino, 2022). Their original use, from the 1960s, was medical nutrition for fat malabsorption, chylothorax (lymph fluid leaking into the chest), liver disease and premature infants, because absorption bypasses bile and the lymphatic system.

In 1971 Huttenlocher introduced the MCT ketogenic diet for childhood epilepsy, allowing more carbohydrate than the classical version (Huttenlocher et al., 1971). A randomized trial later found the two diets comparable (Neal et al., 2009).

From the 1980s, research on faster fat burning made MCTs a candidate for weight control, with programs in North America and Japan (St-Onge & Jones, 2002). In the 2000s the brain-energy hypothesis drove Alzheimer’s research: Accera, the product’s maker, reported cognitive gains with caprylic triglyceride (AC-1202) in 2009, although a re-analysis excluding participants assigned by an unblinded monitor showed no overall effect (Henderson et al., 2009). The product was marketed as Axona, a medical food (a category for foods used under medical supervision) (Roman, 2010). A larger trial of a reformulation (AC-1204) by Cerecin, the successor company, found no benefit (Henderson et al., 2020), and the company has since registered a new phase 3 trial of a different formulation. Meanwhile MCT-enriched coffee and ketogenic diets made MCT oil a mainstream consumer product. Opinion has moved from enthusiasm toward a view that effects are real but modest, with independent replication the main gap.

Expected Benefits

High 🟩 🟩 🟩

Modest Reduction in Body Weight and Body Fat ⚠️ Conflicted

Replacing dietary long-chain fat with MCTs, not adding them, modestly reduced weight, waist and body fat, likely via faster fat oxidation and lower intake. Mumme’s 13-trial meta-analysis (Mumme & Stonehouse, 2015) agrees with independent analyses by Bueno’s group (Bueno et al., 2015) and He’s group (He et al., 2024) and St-Onge’s trial (St-Onge & Bosarge, 2008); commercial bias was detected. A Nestlé-co-funded 6-month trial of 30 g/day versus high-oleic sunflower oil found no weight change (Fortier et al., 2021). Net reading: a small, replicated loss that single trials may miss.

Magnitude: Body weight −0.51 kg versus long-chain fats (95% confidence interval [CI], the range likely to hold the true effect, −0.80 to −0.23 kg) and waist −1.46 cm (95% CI −2.04 to −0.87 cm) (Mumme & Stonehouse, 2015).

Medium 🟩 🟩

Muscle Strength and Function in Frail Older Adults ⚠️ Conflicted

In a 3-month randomized trial in 64 nursing-home residents averaging 85 years, 6 g/day of MCT improved leg movement speed, swallowing and daily-living scores versus the same dose of long-chain fat (Abe et al., 2019). Frail-elder trials come from this one group; a trial by MCT maker Nisshin OilliO found larger knee-strength gains when MCT accompanied walking in healthy older adults (Kojima et al., 2023). A stroke-rehabilitation cohort found MCT alone had limited effect (Yoshimura et al., 2025). Net reading: promising, but resting mainly on one group.

Magnitude: Leg open-and-close test +2.28 repetitions per 10 s with MCT versus −0.59 with long-chain fat, and FIM (Functional Independence Measure, a validated daily-living scale) +5.6 versus −6.6 points (intention-to-treat adjusted means, analysing everyone as randomized; between-group differences significant) (Abe et al., 2019).

Energy Supply in Fat Malabsorption ⭕️ Not Central to Health & Longevity

MCTs are absorbed without bile or lymphatic transport, so they deliver calories when ordinary fat is poorly absorbed. In a randomized crossover trial, patients with short bowel (much of the small intestine surgically removed) and a preserved colon absorbed far more fat on an MCT-containing diet (Jeppesen & Mortensen, 1998). A randomized trial in HIV (human immunodeficiency virus) patients with chronic diarrhea reported fewer and less fatty stools on an MCT formula, compared only with baseline (Wanke et al., 1996). It bears on malabsorption, not longevity.

Magnitude: In short-bowel patients with a colon, fat absorption was 58% on the MCT-containing diet versus 23% on long-chain fat alone, and energy absorption 58% versus 46% (crossover comparison); patients without a colon gained no energy (Jeppesen & Mortensen, 1998).

Low 🟩

Cognitive Function in Healthy Aging, Mild Cognitive Impairment and Alzheimer’s Disease ⚠️ Conflicted

Ketones may fuel glucose-starved brains. Meta-analysis: modest gains in cognitive impairment (Avgerinos et al., 2020). Healthy-elder memory gains in a review (Giannos et al., 2022); null GSK trial (O’Neill et al., 2019). Positive Nestlé-co-authored trial (Fortier et al., 2021); null Cerecin trial (Henderson et al., 2020). Net reading: unconfirmed.

Magnitude: Combined cognitive score SMD (standardized mean difference, effect in standard-deviation units) −0.29 versus placebo (95% CI −0.55 to −0.03) (Avgerinos et al., 2020); NOURISH AD difference on ADAS-Cog (a 70-point Alzheimer’s cognition scale, lower is better) −0.76 points, not significant (Henderson et al., 2020).

Seizure Control in Drug-Resistant Epilepsy ⭕️ Not Central to Health & Longevity

The carbohydrate-restricted, MCT-rich ketogenic diet reduced childhood seizures about as well as the classical diet (Neal et al., 2009), likely via ketosis and decanoic acid. Evidence is indirect: most trials paired MCT with carbohydrate restriction; MCT-alone data are very uncertain (Pellizzari et al., 2026). It bears on epilepsy, not longevity.

Magnitude: Ketogenic diets (classical and MCT arms pooled) cut seizures to 62.0% of baseline versus 136.9% in controls at 3 months, a 75% decrease (95% CI 42.4–107.4%) (Neal et al., 2008); MCT and classical diets did not differ (Neal et al., 2009).

Endurance Exercise Performance ⚠️ Conflicted

MCT added to a carbohydrate drink, sparing muscle sugar stores, shortened a 40-km cycling time trial in one small study (Van Zyl et al., 1996). A similar trial found no added benefit (Angus et al., 2000); a review found negligible effect (Chapman-Lopez & Koh, 2022). Net reading: no reliable gain.

Magnitude: 100-km time trial 169 min with carbohydrate plus MCT versus 166 min with carbohydrate alone, no added benefit (Angus et al., 2000).

Speculative 🟨

Improved Insulin Sensitivity ⚠️ Conflicted

Pooled trials (He et al., 2024) and a diabetes trial (Han et al., 2007) report lower HOMA-IR (an unvalidated insulin-resistance index); an uncontrolled study found unchanged insulin sensitivity (Thomas et al., 2019). Net reading: unproven.

Lifespan Extension ⚠️ Conflicted

A National Institute on Aging program found MCT oil did not extend mouse lifespan (Strong et al., 2013); decanoic acid extended lifespan in disease-model flies, healthy flies untested (Zhang et al., 2025). Net reading: unsupported.

Benefit-Modifying Factors

  • APOE4 status: APOE4 (a fat-transport gene variant raising Alzheimer’s risk) non-carriers showed most cognitive gain in the AC-1202 trial and a later meta-analysis (Henderson et al., 2009; Sun et al., 2023); NOURISH AD found none in non-carriers (Henderson et al., 2020).
  • Baseline carbohydrate intake and blood ketones: Carbohydrate eaten with C8 lowers the ketone response (Frenser et al., 2024), and ketones roughly double when MCT is taken without a meal (St-Pierre et al., 2019).
  • Baseline body weight: The rise in fat burning with MCT was larger in people with lower initial body weight (St-Onge & Jones, 2003), so weight effects may be smaller in people with more obesity.
  • Baseline cognitive status: Memory gains in non-demented older adults appeared larger in those with lower starting scores (Giannos et al., 2022).
  • Sex: No consistent sex difference in benefit has been reported; trials adjusted for sex rather than testing it (Fortier et al., 2021).
  • Pre-existing conditions: Signals are strongest in frailty and mild cognitive impairment; established Alzheimer’s dementia showed no benefit in the largest trial (Henderson et al., 2020).
  • Age: Muscle-function trials enrolled people in their mid-80s (Abe et al., 2019); healthy young adults showed short-term working-memory gains at 12 g/day (Ashton et al., 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Side Effects

Diarrhea, abdominal cramping, bloating and nausea are the dominant adverse events of oral MCT, especially on an empty stomach, at higher doses, or without gradual dose increases. Rapid, bile-independent fat absorption that draws water into the bowel is the proposed mechanism. Placebo-controlled trials by Henderson’s group at Accera (Henderson et al., 2009) and Fortier’s group in Sherbrooke (Fortier et al., 2021), and a systematic review of 33 studies (Scheller et al., 2026), document these effects, with moderate-to-severe reactions and dropouts not uncommon. Effects reverse with dose reduction.

Magnitude: Gastrointestinal adverse events in 48.8% on 20 g/day caprylic triglyceride versus 27.3% on placebo; diarrhea 24.4% versus 13.6%; withdrawal for adverse events 23.3% versus 6.1% (Henderson et al., 2009). Over 6 months, 74% on 30 g/day versus 40% on placebo reported at least one adverse event (Fortier et al., 2021).

Medium 🟥 🟥

No risk reaches Medium: the lipid meta-analyses conflict, and the other harms rest on case reports, isolated laboratory findings or mechanism.

Low 🟥

Adverse Blood-Lipid Changes ⚠️ Conflicted

One meta-analysis found a small triglyceride (blood fat) rise, and an LDL (“bad” cholesterol) rise when this saturated fat replaced unsaturated oils (McKenzie et al., 2021). Other meta-analyses found unchanged lipids (Mumme & Stonehouse, 2015) or lower triglycerides (He et al., 2024). Net reading: mostly neutral, except versus unsaturated oils.

Magnitude: Triglycerides +0.14 mmol/L versus other fats (95% CI 0.01 to 0.27); LDL +0.02 mmol/L (95% CI −0.13 to 0.17) (McKenzie et al., 2021).

Essential Fatty Acid Deficiency When MCT Replaces Most Dietary Fat

Four infants with liver disease fed a high-MCT formula developed essential fatty acid deficiency (shortage of fats the body cannot make) (Pettei et al., 1991). Evidence is uncontrolled and indirect (infants, near-exclusive MCT fat).

Magnitude: 4 of 4 infants showed biochemical deficiency (no control group) (Pettei et al., 1991).

Dehydration and Kidney-Marker Rises in Older Adults ⚠️ Conflicted

In an Alzheimer’s trial of AC-1202, seven MCT recipients had notable rises in BUN (blood urea nitrogen, a kidney waste marker), creatinine or uric acid, mostly linked to dehydration or prior illness (Henderson et al., 2009). Serum chemistry did not differ from placebo overall. Net reading: isolated, not group-level, rises.

Magnitude: 7 participants on AC-1202 had notable rises (no placebo-group count reported); serum chemistry did not differ significantly between groups (Henderson et al., 2009).

Speculative 🟨

Hepatic Encephalopathy in Advanced Cirrhosis ⚠️ Conflicted

Hepatic encephalopathy (confusion caused by liver failure) prompts caution in monographs (drugs.com), but a small study found no clinical or brain-wave changes in cirrhosis (Morgan et al., 1974). Net reading: theoretical concern.

Rise in the Inflammatory Signal Interleukin-8

Over 6 months, interleukin-8 (an immune signaling protein) rose 147% on 30 g/day MCT, significantly more than on placebo. Its clinical meaning is unknown; other inflammatory markers were unchanged (Myette-Côté et al., 2021).

Ketoacidosis in Susceptible People

Ketoacidosis (dangerous acid build-up from excess ketones) is a mechanistic concern only: MCT adds ketones in people already prone to them. No adult case series was found.

Risk-Modifying Factors

  • MCAD deficiency: Variants in the gene for medium-chain acyl-CoA dehydrogenase (the enzyme that breaks down medium-chain fats) make MCT dangerous; newborn screening detects the disorder in most developed nations, and management excludes medium-chain fats (Mason et al., 2023).
  • APOE4 status: Adverse-event rates were similar in APOE4 carriers and non-carriers (Henderson et al., 2009).
  • Baseline lipids: LDL rose when MCT replaced olive or other unsaturated oils (McKenzie et al., 2021); no trial analyzed baseline LDL, though people already high have the least margin for a rise.
  • Sex: No sex differences in side effects have been reported; trials did not analyze them separately.
  • Pre-existing conditions: Diarrheal conditions, advanced cirrhosis, type 1 diabetes and use of SGLT2 inhibitors (diabetes drugs that make the kidneys excrete glucose) raise risk, the last two through ketoacidosis.
  • Age: Older adults may be more vulnerable to diarrhea-related dehydration; in older people with Alzheimer’s disease, kidney-marker rises on MCT were mostly attributed to dehydration (Henderson et al., 2009).

Key Interactions & Contraindications

  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Caution (theoretical). These diabetes drugs raise ketones; adding MCT may increase ketoacidosis risk. Mitigation: blood-ketone checks during illness or fasting.
  • Insulin and sulfonylureas (insulin-releasing diabetes drugs such as glipizide, glimepiride): Monitor (theoretical). Replacing carbohydrate with MCT lowers carbohydrate intake and may lower glucose, risking hypoglycemia (low blood sugar). Mitigation: glucose monitoring when starting.
  • Valproate (valproic acid, divalproex): Monitor (theoretical). Valproate is itself a branched medium-chain fatty acid processed by liver fat oxidation; combined use with MCT ketogenic diets could add liver load. Mitigation: liver enzymes under specialist supervision.
  • Lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe): Monitor (theoretical). Human data show LDL rises when MCT replaces unsaturated oils, which may offset treatment; no interaction study exists (McKenzie et al., 2021). Mitigation: a repeat lipid panel 8–12 weeks after starting.
  • Laxatives and stool softeners (bisacodyl, docusate, magnesium citrate): Caution (theoretical) for over-the-counter use. Additive diarrhea and dehydration. Mitigation: no combined use during MCT dose increases.
  • Fat-soluble vitamins and beta-carotene (vitamins A, D, E, K): Monitor (beta-carotene, vitamin A); theoretical otherwise. With MCT as the only fat, the beta-carotene and vitamin A blood response was markedly lower than with long-chain fat (Borel et al., 1998). Mitigation: intake with long-chain fat.
  • Exogenous ketones (ketone esters, beta-hydroxybutyrate salts): Caution (theoretical). Additive ketosis and gastrointestinal upset. Mitigation: introduction of one product at a time.
  • Caffeine (coffee, caffeine tablets): Monitor. In a controlled human study, 150 mg caffeine added to the ketone rise from MCT, most with C8 (Baumeister et al., 2021). Consequence: additive ketosis and gastrointestinal upset. Mitigation: caffeine added only once the MCT dose is tolerated.
  • Coconut oil and other saturated-fat supplements: Monitor (theoretical). Additive saturated-fat load and possible LDL rise. Mitigation: all added fats counted together.
  • Ketogenic diets and fasting: Monitor. MCT taken without a meal roughly doubles the ketone response (St-Pierre et al., 2019), potentiating ketosis and gastrointestinal effects. Mitigation: lower doses during fasting.
  • High-carbohydrate meals: Monitor. Carbohydrate eaten at the same time blunts C8-induced ketone production (Frenser et al., 2024). Consequence: reduced ketone benefit, not harm. Mitigation: dosing with low-carbohydrate meals when ketones are the goal.

Populations who should avoid Medium-Chain Triglycerides:

  • MCAD deficiency or other medium-chain fatty acid oxidation disorders: avoid.
  • Advanced liver disease, including cirrhosis, portal hypertension (high pressure in the liver’s blood supply), hepatic encephalopathy or a portacaval shunt (surgical bypass around the liver): use only after medical review (drugs.com); one study found no clinical or brain-wave change in cirrhosis (Morgan et al., 1974).
  • Uncontrolled diabetic ketoacidosis: avoid (theoretical).
  • Pregnancy and breastfeeding at supplement doses: caution (theoretical), as no safety trials exist.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Gradual dose increase: Prevents gastrointestinal side effects; the ALTER-AD trial raises the dose from 5 g twice daily to 20 g twice daily over 2–4 weeks (NCT05809908).
  • Dosing with food: Reduces diarrhea and nausea; ALTER-AD gives each dose 30 minutes after a full meal (NCT05809908), at the cost of a smaller ketone rise.
  • Split doses: Lowers the gastrointestinal load per dose and limits gastrointestinal upset; 15 g twice daily was used for 6 months (Fortier et al., 2021).
  • Unsaturated oils retained in the diet: Limits the LDL rise seen when MCT displaces unsaturated oils (McKenzie et al., 2021) and preserves essential fatty acids (Pettei et al., 1991).
  • Lipid check: A fasting lipid panel at baseline and 8–12 weeks detects adverse LDL or triglyceride shifts.
  • Hydration in older adults: Fluids during dose increases and stopping during diarrhea guard against dehydration, which accompanied kidney-marker rises on MCT in an Alzheimer’s trial (Henderson et al., 2009).
  • Fat-soluble supplements paired with long-chain fat: Prevents the lower carotenoid and vitamin A transport into the blood seen with MCT alone (Borel et al., 1998).

Therapeutic Protocol

Timing, cycling and dose-increase steps below follow common practice unless cited.

  • Cognitive-support regimen (Sherbrooke): 30 g/day of a ketogenic MCT drink, 15 g twice daily with meals for 6 months (Fortier et al., 2021).
  • Alzheimer’s drug-development regimen: 20 g/day caprylic triglyceride in the AC-1202 trial (Henderson et al., 2009); up to 40 g/day tricaprilin in the planned ALTER-AD trial (NCT05809908).
  • Body-composition regimen: 18–24 g/day MCT oil replacing olive oil within a weight-loss diet for 16 weeks (St-Onge & Bosarge, 2008).
  • Frailty regimen: 6 g/day MCT with a meal, breakfast or dinner equally effective (Abe et al., 2019; Abe et al., 2022).
  • Practitioner approach: Chris Kresser suggests starting with one tablespoon daily split into three teaspoons, rising to two tablespoons (Kresser Institute); for Alzheimer’s, he describes 6–9 tablespoons daily of a 50/50 MCT and coconut oil mix (Kresser podcast).
  • Competing formulations: Pure C8 maximizes ketones; C8/C10 blends dominate trials; coconut oil yields about a quarter of C8’s ketone peak (Vandenberghe et al., 2017). A full ketogenic diet is the higher-effort alternative.
  • Time of day: Morning doses suit ketone goals; taken without a meal, MCT roughly doubles ketones (St-Pierre et al., 2019). Muscle effects did not depend on timing (Abe et al., 2022).
  • Half-life: MCT fatty acids are burned for energy within hours; plasma ketones peak 0.5–3 hours after a dose (St-Pierre et al., 2019) and were back at baseline before the next day’s dose (Henderson et al., 2009).
  • Single versus split dosing: Split doses (two or three per day) sustain ketones across the day and improve tolerance.
  • Genetic factors: APOE4 non-carriers showed larger cognitive responses (Sun et al., 2023); MCAD deficiency excludes use.
  • Sex: No sex-specific dosing exists; trials used the same doses in women and men.
  • Age: Older and frail adults responded to doses as low as 6 g/day (Abe et al., 2019) and are more sensitive to diarrhea, favoring lower starting doses.
  • Baseline biomarkers: High LDL argues for replacing saturated rather than unsaturated fats; carbohydrate eaten with a dose lowers the ketone response (Frenser et al., 2024).
  • Pre-existing conditions: Diabetes on SGLT2 inhibitors, cirrhosis and irritable bowel call for lower doses or medical supervision; epilepsy diets require specialist teams.

Discontinuation & Cycling

  • Duration of use: Benefits are tied to ongoing intake; trials ran 3–6 months, and no data show lasting effects after stopping, so use is open-ended rather than a fixed course.
  • Withdrawal effects: None reported; cognitive differences and ketone elevations disappeared after a 2-week washout (Henderson et al., 2009).
  • Tapering: Not needed for safety; MCT can be stopped abruptly.
  • Cycling: No evidence that cycling maintains efficacy; continuous daily use was studied in all trials.

Sourcing and Quality

  • MCT oil versus coconut oil: Coconut oil’s medium-chain fat is mostly lauric acid (C12), which behaves largely like a long-chain fat; coconut oil holds 3% C8 and 5% C10 versus 55% C8 and 35% C10 in a classical MCT oil (Vandenberghe et al., 2017).
  • Label checks: Labels that state C8 and C10 content separately show how much of the oil is the more ketogenic C8; products listing only “total MCTs” may include C12.
  • Powders: MCT powders bound to acacia fiber or starch may be better tolerated gastrointestinally but carry less MCT per gram and added carbohydrate.
  • Third-party testing: NSF International or USP (United States Pharmacopeia) seals add assurance on contaminants and label accuracy.
  • Brands: Widely used options include Nestlé Health Science MCT Oil (medical nutrition), Bulletproof Brain Octane (pure C8) and NOW Foods MCT Oil; trial products were proprietary (Nestlé, Cerecin, Nisshin OilliO).
  • Source oil: MCTs come from coconut or palm kernel oil; palm-derived products vary in sustainability certification (e.g., RSPO, Roundtable on Sustainable Palm Oil).

Practical Considerations

  • Time to effect: Ketones rise within hours; weight changes appeared over 4–16 weeks (Examine); muscle function at 1.5–3 months (Abe et al., 2019); cognition at 3–6 months.
  • Common pitfalls: Starting at full dose, adding MCT without cutting other fats, swapping in coconut oil expecting the same ketones, and taking MCT with high-carbohydrate meals that blunt ketosis.
  • Regulatory status: In the United States MCT oil is sold as a food and supplement; a 2012 GRAS (generally recognized as safe) notice to the Food and Drug Administration was closed at the notifier’s request (FDA GRN 449). Tricaprilin is in drug trials.
  • Cost: Inexpensive and widely sold as a food product; the proprietary trial formulations (e.g., tricaprilin) are not available outside studies.
  • Funding and payer incentives: Generic MCT oil is unpatentable and paid out of pocket, so insurers have no stake in it, while large trials are funded by firms holding patented formulations (Accera/Cerecin, Nestlé), a structural bias toward proprietary products.

Interaction with Foundational Habits

  • Sleep: No direct interaction known (none). Frailty trials dosed MCT at dinner but did not report on sleep (Abe et al., 2022); large late doses may cause night-time gastrointestinal discomfort, so earlier dosing is a practical option.
  • Nutrition: Potentiating with low-carbohydrate diets and fasting, which amplify ketones; blunted by carbohydrate eaten at the same time (Frenser et al., 2024). Weight trials replaced rather than added dietary fat, and meals with long-chain fats preserve the blood response to carotenoids and vitamin A (Borel et al., 1998).
  • Exercise: No ergogenic (performance-enhancing) effect for endurance (Chapman-Lopez & Koh, 2022); about 30 g appears the upper limit before exercise to avoid gastrointestinal distress (same review). Indirect potentiation with resistance exercise: MCT plus chair-stand training improved function more than MCT alone in stroke rehabilitation (Yoshimura et al., 2025).
  • Stress management: No direct interaction (none); no human data exist on cortisol or stress response. Combining MCT with large caffeine doses for “energy” may add jitteriness and gastrointestinal upset, and caffeine itself raises ketones (Vandenberghe et al., 2017).

Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes reference points: a fasting lipid panel, body weight and waist circumference, and, for people with memory concerns, a brief cognitive screen. For people with liver disease, those taking valproate, and frail older adults, protocols add baseline liver enzymes and creatinine. An optional pre-dose and 2-hour post-dose ketone reading shows whether a chosen product and dose actually raise ketones.

Ongoing monitoring follows this cadence: ketones during the first 1–2 weeks of dose increases, lipids and weight at 8–12 weeks, then every 6–12 months; cognitive screens every 6–12 months for those with cognitive complaints; creatinine within 2–4 weeks in frail older adults who develop diarrhea. Success means the targeted change appears within 3–6 months without adverse lipid shifts or persistent gastrointestinal symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL cholesterol <100 mg/dL “optimal” (NCEP ATP III) Safety check: may rise if MCT replaces unsaturated oils NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III (guideline); conventional laboratory reference range typically <130 mg/dL (lab-dependent); fasting 9–12 hours
Triglycerides <150 mg/dL “normal” (NCEP ATP III) Safety check: small rise reported with MCT oil Source: NCEP ATP III; conventional laboratory reference range <150 mg/dL; fasting sample, same lab each time
Beta-hydroxybutyrate (blood ketone) No established target; track the 2-hour post-dose rise against the person’s own pre-dose value Expected change: confirms the product raises ketones The AC-1202 trial saw about 0.36–0.39 mmol/L 2 hours after 20 g (Henderson et al., 2009); finger-stick meters suffice; carbohydrate eaten with the dose lowers readings
Body weight and waist circumference No established target; track change from own baseline Expected change: modest decrease when MCT replaces other fats Morning, fasting, same scale and tape position
ALT 7–55 U/L (standard reference range) Safety check in liver disease or valproate use: a rise prompts review of use ALT = alanine aminotransferase, a liver enzyme released when liver cells are injured; range is lab-dependent
Creatinine 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women (standard reference range) Safety check in frail adults with diarrhea: a rise signals dehydration Creatinine is a muscle waste product cleared by the kidneys; usually paired with blood urea nitrogen; lab-dependent
Cognitive screen (MoCA) No established target; track change from own baseline Expected change in people with cognitive complaints MoCA = Montreal Cognitive Assessment, a 30-point screening test; alternate versions limit practice effects

Qualitative markers:

  • Mental clarity and sustained focus during the day
  • Energy levels and fatigue between meals
  • Appetite and fullness after meals
  • Bowel habits, bloating and abdominal comfort
  • Physical function in older adults, such as rising from a chair or walking speed

Emerging Research

  • ALTER-AD tricaprilin phase 3 (NCT05809908): Cerecin-sponsored, 535 people with mild-to-moderate Alzheimer’s dementia, up to 40 g/day for 26 weeks; primary outcomes ADAS-Cog and clinician-rated change. Not yet recruiting; completion expected 2029. Positive: cognition could move above Low. Null: would further weaken the dementia case.
  • COGNIKET-MCI (NCT06347315): Nestlé-sponsored, 380 older adults with mild cognitive impairment, ketogenic MCT plus B vitamins versus sunflower oil; primary outcome a preclinical Alzheimer’s cognitive composite. Recruiting; completion December 2027. Positive: supports the combination, not MCT alone. Null: would undercut the Sherbrooke findings.
  • Mediterranean diet with MCT in new mild cognitive impairment (NCT06951932): 120 participants, 30 mL/day MCT versus extra-virgin olive oil. Registered completion November 2025 has passed; still listed as recruiting, no results posted. Positive: hospital-led support for cognition (industry collaborator: Dr. Schär). Null: would favor olive oil.
  • Post-COVID cognitive symptoms (NCT05705648): University of Alberta, 103 participants, MCT oil versus safflower oil, computerized cognitive testing. Active, not recruiting; completion March 2027. Positive: broadens brain-fuel evidence beyond dementia. Null: would narrow MCT’s cognitive role to neurodegeneration.
  • Long-term lipid and cardiovascular effects: Existing lipid trials lasted weeks to months (McKenzie et al., 2021); year-long trials measuring LDL particles against an unsaturated-oil control could confirm or remove the main cardiovascular concern.
  • Lifespan and healthspan: MCT oil failed to extend mouse lifespan in the Interventions Testing Program (Strong et al., 2013); healthspan studies of pure C8 could still reveal benefits on brain or muscle ageing, or confirm none.
  • Tolerability and formulation: A 2026 review found gastrointestinal effects limit use and long-term tolerability is insufficiently investigated (Scheller et al., 2026); C8-rich emulsions and powders could improve the benefit-to-side-effect balance.

Conclusion

Medium-chain triglycerides are refined fats, mostly from coconut and palm kernel oil, that the body absorbs quickly and partly converts into ketones, a backup fuel for the brain. For health-focused adults, the most consistent finding is a small reduction in body weight and body fat when these oils replace other fats in the diet, not when they are simply added. Improved muscle function in frail older adults rests mainly on a single research group. Benefits for memory and thinking in early cognitive decline remain uncertain: small studies point to modest gains, mainly in people without the common Alzheimer’s risk gene variant, while the largest trial found no benefit. There is no support for longer lifespan, and no reliable gain in endurance performance.

The main drawback is digestive upset, which is common, dose-related and reversible. Effects on blood fats are mostly neutral, though bad cholesterol can rise when these oils displace olive or other unsaturated oils. People with a rare inherited inability to break down these fats, and those with advanced liver disease, face particular risks.

Much of the research was funded or run by companies that sell these oils or patented versions of them, including the makers of the Alzheimer’s products and large food companies, and independent replication is limited. Overall, the evidence describes a cheap, generally safe food ingredient with modest, well-defined effects on body weight and fat and unproven effects on the ageing brain.

Top - Benefits - Risks - Protocol